Fig. 1: QC enhances vorinostat-inhibited cell viability in T-ALL cells. | Cell Death & Disease

Fig. 1: QC enhances vorinostat-inhibited cell viability in T-ALL cells.

From: Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition

Fig. 1: QC enhances vorinostat-inhibited cell viability in T-ALL cells.

a, b Jurkat and Molt-4 cells were treated with the indicated dose of vorinostat or QC for an indicated time or the combination of both, and then the cell viability were monitored by trypan blue staining. c, d Jurkat cells were treated with vorinostat (1 μM) and/or QC (5 μM) and Molt-4 cells were treated with vorinostat (1 μM) and/or QC (2.5 μM) for an indicated time. Cell viability was monitored by trypan blue staining (c). The morphology of the cells was observed by Wright staining (d). e CIs were analyzed with the program CompuSyn in Jurkat and Molt-4 cells. CI value <1 indicates that the two drugs have synergic effects. f PBMCs from T-ALL patients were treated with vorinostat (1 μM) and QC (5 μM) for 24 and 48 h, and the cell viability was monitored by trypan blue staining. g PBMCs were treated with vorinostat (1 μM) and QC (5 μM) for 48 h, and the cell viability was monitored by trypan blue staining. *p < 0.05, **p < 0.01, and ***p < 0.001. All experiments were performed at least three times with the same results

Back to article page